A phase I/II clinical trial for treating malignant melanoma by boron neutron capture therapy (BNCT) was designed to evaluate whether the world's first in-hospital neutron irradiator (IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the cl...

Boron Neutron Capture Therapy (BNCT) is neutron radiotherapy used to treat tumours cells previously doped with Boron-10. This therapy requires an epithermal beam for the treatment of deep and a thermal shallow ones. Thanks recent high-current commercial accelerators, Accelerator-Based Sources (ABNS) are competitive option providing therapeutic beams in hospitals. In this work, field generated b...

In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of bo...

Background: Boron neutron capture therapy (BNCT) is a binary modality based on the nuclear reaction 10B (n, α) lithium-7 (7Li) that has been used to treat variety of tumors, among these, cutaneous melanoma (CM). In previous boron biodistribution studies in agreement with personalized oncology, we have demonstrated boronophenylalanine (BPA) uptake can be correlated tumoral temperature and viabil...

We treated a 54-year-old Japanese female with a recurrent radiation-induced osteosarcoma arising from left occipital skull, by reactor-based boron neutron capture therapy (BNCT). Her tumor grew rapidly with subcutaneous and epidural extension. She eventually could not walk because of cerebellar ataxia. The tumor was inoperable and radioresistant. BNCT showed a marked initial therapeutic effect:...

Abstract Boron neutron capture therapy (BNCT) is a potential radiation modality for cancer, and tumor-targeted stable boron-10 ( 10 B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro- closo -dodecaborate (BSH) boronophenylalanine (BPA), mainly used in Although both have suboptimal tumor selectivity, t...

background: the aim of this work was to establish how well gel dosimeters performed, as substitutes for brain tissue compared with standard phantom materials such as water, polymethyl-methacrylate (or pmma), a150 plastic and te- liquid phantom material for dosimetry of neutron beams in boron neutron capture therapy. materials and methods: thermal neutron fluence, photon dose and epithermal neut...

This study aimed to evaluate the residual radioactivity in mice induced by neutron irradiation with an accelerator-based boron neutron capture therapy (BNCT) system using a solid Li target. The radionuclides and their activities were evaluated using a high-purity germanium (HP-Ge) detector. The saturated radioactivity of the irradiated mouse was estimated to assess the radiation protection need...